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The aim of this study was to investigate whether cognitive performance was equally
influenced by Apolipoprotein E (APOE, with its three alleles, e2, e3, and e4) in patients
with subjective cognitive decline (SCD), mild cognitive impairment (MCI), and Alzheimer’s
disease (AD). In addition, we examined a group of patients with a combination of
Vascular dementia (VaD) and AD (VaD/AD). We asked if the APOE e4 allele influenced
cognition in these patient groups in the same way. Our study comprised data from
1,991 patients (55% women), with a mean age of 70.9 years (SD 10.8) and 12.1 years
of education (SD 3.8). Of them, 1,111 (56%) had at least one APOE e4 allele; 871
(44%) had one and 240 (12%) had two e4 alleles. Three neurocognitive tests were used
to measure cognition: the Mini Mental State Examination (MMSE), the 10-word test
of the Consortium to Establish a Registry for Alzheimer’s Disease Word List (CERAD-
WL) (immediate and delayed recall), and the Trail Making Test Part A (TMTA). The
APOE genotypes were regressed against cognitive function using linear regression,
adjusting for diagnosis, age, sex, and education. The interaction diagnosis∗APOE was
investigated. The allele type had the largest effect on cognitive performance assessed
by the CERAD-WL delayed recall test, less for the other tests. Those without the e4
type scored 0.7 units better than those with e4 allele(s) (p < 0.001). Furthermore,
there was a significant inverse dose-response pattern between number of e4 alleles
and cognitive performance; those with one allele scored 0.4 units better than those with
two alleles (p = 0.006), and those without e4 scored 0.7 units better than those with one
e4 (p < 0.001). This pattern did not differ between the four diagnostic groups studied.
Keywords: cognition, memory difficulties, minor neurocognitive disorders, major neurocognitive disorders,
dementia, APOE e4 status
INTRODUCTION
The human Apolipoprotein E (APOE) gene has three common allelic variants—e2, e3, and e4—
which are encoded on chromosome 19 (Mahley et al., 2009). Depending on the genetic variability,
the APOE gene has been ascribed significant positive and negative health effects such as longevity
and shortened lifespan, neurological and psychosomatic disorders, cognitive decline and Alzheimer
disease, altered lipoprotein profile, atherosclerosis and cardiovascular disease, type II diabetes,
changes in the immune response, oxidative stress, quality of life, physical activity, and obesity
(Spinney, 2014; Klimentidis et al., 2018; Abondio et al., 2019; Kulminski et al., 2019). The e4 allele
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has been ascribed poor health outcomes and the e2 has been
associated with health-promoting effects (Farlow et al., 2004; Fan
et al., 2006; Julian et al., 2009; Chou, 2010; Suri et al., 2013;
Spinney, 2014; Kulminski et al., 2016; Abondio et al., 2019).
According to a review of several studies, it is well known that
persons with the e4 allele have an increased risk of developing
Alzheimer’s disease (AD) compared with persons without the e4
allele (Saunders et al., 1993). This finding could be secondary
to a dosage effect, as persons with homozygote combinations
of APOE e4 (e4/e4) have the highest risk for development and
early onset of dementia due to AD (Verghese et al., 2011). The
clinical hallmark of AD is, among other factors, a progressive
decline in episodic memory (McKhann et al., 2011), and a
substantial number of studies have reported that the e4 allele
contributes significantly to this progressive decline (El Haj et al.,
2016). Even though there seems to be a dose-dependent risk
regarding the development and course of the second most
common dementia type, Vascular dementia (VaD), with a higher
risk related to homozygote e4 alleles, more studies are needed to
understand how VaD and Apo E status are related to each other
(Verghese et al., 2011).
In addition, studies have shown that age-related memory
decline in healthy individuals differs between e4 carriers and
non-carriers (Caselli et al., 2009). For carriers of e4, decline
started before age 60 and accelerated faster than in non-carriers.
Those with homozygotic e4 alleles demonstrated the strongest
acceleration (Caselli et al., 2009).
Various theories exist to explain how the APOE e4 allele affects
the brain. One theory is that the different APOE e variants have
various effects on amyloid-β accumulation (cerebral amyloid
angiopathy and fibrinogen deposits) in the brain (Hultman et al.,
2013). It is further suggested that the e4 variant increases blood-
brain-barrier damage (Zipser et al., 2007). Another theory is
that the various APOE alleles cause differences in binding and
clearance of Aβ (Bell et al., 2007; Deane et al., 2008).
As the e4 allele is reported to have a negative effect on episodic
memory in both normal aging and AD, we examined whether the
APOE e4 allele affected cognition, especially episodic memory,
equally in persons with subjective cognitive decline (SCD), mild
cognitive impairment (MCI), and dementia due to AD.
We further explored the relationship between cognition and
APOE genotypes in patients with a diagnosis of mixed VaD/AD.
We hypothesized that people with the APOE e4, either
heterozygote or homozygote, would have a different relationship
with cognitive performance than non-e4 carriers would,
regardless of SCD, MCI, and AD diagnoses, whereas no
hypothesis is offered for the group with mixed VaD/AD. We
further hypothesized that test scores would be worse in the
dementia groups than in the SCD and MCI groups.
MATERIALS AND METHODS
Norwegian Register of Persons
Assessed for Cognitive Symptoms
Our study population came from the Norwegian Register of
Persons Assessed for Cognitive Symptoms (NorCog), included
and diagnosed during the period 2009–2018. NorCog is a
national research and quality register for persons referred to
the specialist health care service for assessment of memory
impairment and possible dementia. The register is consent-based
and has existed since 2009; 42 outpatient clinics currently collect
these data from regular patients. NorCog is licensed by the
Norwegian Data Inspectorate until 2030. Of those patients asked
to give consent, 90% have answered positively and signed a
consent form. The data collected in the register include a wide
battery of neuropsychological tests, a comprehensive physical
examination, blood-sample collection for various types of
analyses, and cerebral imaging with magnetic resonance imagery
or computed tomography (Braekhus et al., 2011). In addition, and
in accordance with the Norwegian national guidelines regarding
dementia, fluorodeoxyglucose-positron emission tomography
(FDG-PET) and examination of concentration of amyloid-beta
and tau protein in cerebrospinal fluid are increasingly performed
in many patients with an uncertain diagnosis.
Diagnoses
The dementia diagnoses recorded in NorCog are based on
the International Classification of Diseases (ICD-10) criteria
for research (World Health Organization [WHO], 1993) and
made by experienced neurologists, geriatricians, or geriatric
psychiatrists, usually in consensus meetings. The Winblad
criteria are used for MCI (Winblad et al., 2004), and patients
who complain about cognitive decline but show no cognitive
impairment are given the diagnosis of SCD, in accordance
with the Jessen criteria (Jessen et al., 2014). Patients diagnosed
with SCD, MCI, AD, VaD and mix VaD/AD were included
in the analyses (VaD and the mixed VaD/AD groups were
combined). Patients with dementia due to Parkinson’s and Lewy
body disease, Frontotemporal dementia (FTD) and unspecific
dementia or dementia due to rare causes were excluded because
of small samples with ApoE information. The patients are
newly diagnosed in connection with their first assessments
at an out-patient clinic in specialist health care for the
elderly. The diagnoses were based on clinical examinations,
including neuropsychological testing and MRI or CT of the
brain. In additions, depending on clinical indication, extended
neuropsychological tests were performed, CSF was analyzed (beta
amyloid and tau protein), or FDG-PET was carried out. If AD
was diagnosed, patients were offered cholinesterase inhibitor
treatment immediately at the time of diagnosis.
Study Population
The initial NorCog population comprised 10,457 patients, of
which APOE information was recorded for 2,549 patients from
five clinics. (No other clinics had APOE genotyped patients.) Of
the 2,549 patients, we included 1,991 [Aker hospital (n = 173),
Innlandet hospital (n = 231), Ullevål hospital (n = 1,017),
Haugesund hospital (n = 80), and St. Olavs hospital (n = 490)]
with a diagnosis of SCD, MCI, AD or mixed VaD/AD. Patients
with other dementia diagnosis and APOE information were
excluded because of the small number of patients in each
diagnostic group.
Frontiers in Psychology | www.frontiersin.org 2 June 2021 | Volume 12 | Article 686036
fpsyg-12-686036 June 8, 2021 Time: 16:52 # 3
Hestad et al. Cognition in Patients With Memory Difficulties
The Cognitive Test
The following cognitive tests were applied: The Mini Mental state
examination (MMSE) (Folstein et al., 1975), the Consortium to
Establish a Registry for Alzheimer’s Disease Word List (CERAD-
WL) (immediate and delayed recall) (Morris et al., 1988; Hankee
et al., 2016) and the Trail Making Test Part A (TMTA). MMSE
is a well-known screening test for cognition that includes items
measuring orientation, attention, memory, language, and visual-
spatial skills. It includes 11 questions and takes 7–10 min to
administer. Scores range from 0 to 30, with a higher score
indicating better performance. A cut of between 24/23 is often
used as a healthy/dementia indicator. The CERAD-WL test
consists of 10 words presented over three learning trials, and a
delayed recall trial presented 10 min after trial 3 administration.
The maximum score for the learning trials is 30, and for delayed
recall 10, with a higher score indicating better performance.
Here normative data were available both from Norwegian and
other populations (Morris et al., 1988; Spreen and Strauss, 1991;
Kirsebom et al., 2019). The TMTA consists of 25 encircled
numbers randomly arranged on a page; the participant is asked to
draw a line through the circles in proper numerical order (Strauss
et al., 2006). We recorded the time required in seconds to perform
the test without mistakes, with a shorter time denoting better
performance. There are many different norms developed related
to the Trail Making test, most of these are summarized in Strauss
et al. (2006).
The tests were administered by a trained nurse, a physician
or psychometrician. The raw scores of the tests were used
in the analyzes.
APOE-Genotyping
Genotyping was performed using real-time PCR with allele-
specific fluorescence energy transfer probes and melting curve
analyses on a LightCycler 480 (Roche, Mannheim, Germany),
with sense (GAAGGCCTACAAATCGGAACTG) and antisense
(GGCTGCCCATCTCCTCCATC) primers and detection probes
(LC-red705- ACATGGAGGACGTGCGCGG-Phosphate;
NM_000041.3 [APOE]: c.388T > C variant nucleotide
underlined) for the ε4 allele with the corresponding anchor
probe (CTGCAGGCGGCGCAGGCCCGGCTGGGCGC-
fluorescein). The 20 µL PCR reaction mix consisted of 1x
LightCycler 480 Probes Master, 0.1 µM of sense and 0.5 µM
of antisense primers, 0.14 µM of each probe, 10% dimethyl
sulfoxide, and 5 µL of diluted DNA eluate (10–100 ng). The
PCR touchdown protocol consisted of denaturation of DNA
and activation of the polymerase (95◦C, 5 min); 40 cycles of
denaturation (95◦C, 10 s), annealing (63◦C stepping down
0.4◦C/cycle to 59◦C, 10 s), elongation (72◦C, 10 s); denaturation
and polymerase inactivation (99◦C, 10 min); and melting curve
analysis [38◦C (1 min) to 77◦C (ramp rate 1◦C/s)]. The ε4 allele
(rs429358) was identified by melting temperature 64◦C vs. 56◦C
for wild type. The laboratory participates in an external quality
assurance program (Equalis, Uppsala, Sweden) that includes
APOE genotyping.
The number of years of education was self-reported. Anti-
dementia medicine use was based on self-reports and coded using
the ATC classification, as a binary variable with value 1 for those
using medicines classified as N06D, and 0 for those not using one
of these medicines.
Statistical Modeling
To investigate cognitive performance by APOE genotype, the
APOE genotypes were regressed against cognitive function (i.e.,
raw scores from the different tests) using linear regression,
adjusting for age, sex, diagnosis, and education. The interaction
between APOE and diagnosis was included to investigate whether
cognitive function by APOE genotype differed by diagnosis.
Predictions of mean cognitive scores, with 95% confidence
intervals (CIs), from the regression models were performed
using the margins commando in Stata with fixed values for
the adjustment covariates (age 75 years, men and women
weighted equally, 12 years of education). Furthermore, to
investigate whether cognitive scores differed among the three
APOE types, the monozygotic e4 was set as reference and the
difference in cognition for those without the e4 and those
with two e4s was predicted (with 95% CIs). Analyses were also
performed without an interaction between APOE and diagnosis,
in the full sample, in the sample restricted to those with a
dementia diagnosis, and in a sample of those with the milder
cognitive diagnoses.
Ethics Statement
The study was reviewed and approved by the study Regional
Ethics Committee for Medical and Biological Research (REK:
2019/316), and all participants gave written informed consent to
participate in this study.
RESULTS
In our study population, 44% had one e4 allele and 12%
had two. The occurrence of e4 differed by diagnosis and was
most prevalent among AD patients (51% monozygotic and 20%
homozygote) and least prevalent among SCD (38% monozygotic,
3% homozygote) and MCI patients (39% monozygotic and 12%
homozygote) (see Table 1). SCD and MCI patients were younger
than patients with a dementia diagnosis (see full APOE genotype
distribution in Supplementary Table 1). Anti-dementia medicine
use was used by 49 of the 1,991 patients (2.5%), mostly among
those with AD (n = 37). The low number was mainly due the fact
that the dementia diagnosis was made after the basic assessment
as described in this article.
Adjusted for age, sex, and education, those with the milder
cognitive diagnoses (SCD and MCI) performed significantly
better than the dementia groups on all cognitive tests. With
similar adjustments, AD patients had the significantly lowest
scores for the CERAD-WL tests. For TMTA, however, AD
patients scored significantly better than patients in the mix+VaD
group. For MMSE, there was no significant difference in scores
among the dementia subgroups.
In crude analyses, e4 carriers with a diagnosis of SCD, MCI,
or AD had significantly poorer cognitive performance on the
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TABLE 1 | Descriptive statistics.
Men Women Age and education Apoe E status, n (%)
Diagnosis n (%) n (%) Mean age (SD) Education, years (SD) No E4 One E4 Two E4
SCD 202 (20) 223 (21) 64.1 (11.5) 13.4 (4.0) 251 (59) 161 (38) 13 (3)
MCI 358 (35) 301 (28) 69.7 (10.6) 12.3 (3.7) 327 (50) 255 (39) 77 (12)
AD 256 (25) 374 (35) 73.5 (9.0) 11.7 (3.7) 181 (29) 324 (51) 125 (20)
VaD/AD 144 (14) 133 (12) 77.8 (6.7) 10.8 (3.4) 121 (44) 131 (47) 25 (9)
Total 960 (100) 1,031 (100) 70.9 (10.8) 12.1 (3.8) 880 (44) 871 (44) 240 (12)
N = 1,991.
CERAD-WL delayed recall test (Table 2) compared to non-
carriers. For e4 carriers with a diagnosis of MCI, this was the
case also for the immediate recall test, and for e4 carriers with
SCD on the MMSE.
In the analyses adjusted by age, sex, and education,
allele type had the largest effect for cognitive performance
assessed by the CERAD-WL delayed recall test, and less
effect on the other tests—apart from immediate recall,
in which the MCI patients without the e4 type scored
significantly better than those with the e4-type (Figure 1).
The interaction APOE by diagnosis was not significant
(p = 0.99), however, suggesting an equal effect of APOE for
all diagnoses.
TABLE 2 | Cognitive scores by diagnosis and E4 status.
No E4 One E4 Two E4
Diagnosis CERAD immediate recall: mean (SD)
SCD 19.2 (4.9) 18.0 (5.6) 17.3 (7.1)
MCI 15.2 (4.4) 14.4 (4.3)* 14.8 (4.0)
AD 10.5 (4.2) 10.0 (4.3) 10.2 (4.3)
VaD/AD 10.4 (3.7) 9.9 (4.5) 9.9 (4.7)
CERAD delayed recall: mean (SD)
SCD 5.8 (2.3) 5.0 (2.7)* 4.0 (3.6)
MCI 3.8 (2.5) 3.0 (2.1)* 2.8 (2.2)*
AD 1.7 (1.8) 1.1 (1.4)* 0.8 (1.4)*
VaD/AD 1.6 (1.8) 1.3 (1.7) 1.2 (1.8)
MMSE: mean (SD)
SCD 28.0 (2.6) 27.3 (3.0)* 26.1 (3.5)
MCI 26.4 (3.1) 26.2 (3.0) 26.2 (2.8)
AD 21.9 (4.2) 21.5 (4.3) 21.5 (4.8)
VaD/AD 21.5 (4.2) 21.4 (3.9) 22.5 (4.2)
TMTA: mean (SD)
SCD 48.2 (37.8) 53.7 (45.0) 73.8 (79.2)
MCI 65.0 (35.7) 63.1 (32.3) 60.8 (28.6)
AD 96.3 (58.4) 91.0 (58.8) 86.8 (53.2)
VaD/AD 111.2 (65.0) 118.4 (67.5) 112.7 (69.7)
*Different from the group with No E4, tested in linear regression, p < 0.05.
Crude mean values (Standard deviations: SD).
Overall, for delayed recall, patients without the e4 allele
scored 0.7 units better than did those with e4 allele(s)
(p < 0.001). Furthermore, there was a significant inverse dose-
response pattern between number of e4 alleles and cognitive
performance; patients with one allele scored 0.4 units better
than did those with two alleles (p = 0.006), and those
without e4 scored 0.7 units better than did those with one e4
(p < 0.001). This pattern did not differ among the diagnostic
groups. When diagnostic groups were analyzed individually,
however, no significant difference between those with two
and one e4 was found, probably due to lack of statistical
power. A significant difference, however, was observed between
patients with no e4 and those with one or two e4s (see
Figure 1B, right panel).
DISCUSSION
The strongest association between APOE e4 and cognition was
observed in the CERAD-WL delayed recall, and this association
was similar across diagnoses (i.e., there was no APOE e4 ∗
diagnosis interaction). The finding concurs with the clinical
hallmark of AD, a progressive reduction of episodic memory
(McKhann et al., 2011). Nevertheless, this association was related
not only to AD; it was found in all the diagnostic groups we
examined. Overall, for the APOE e4, we also found a tendency for
a dose-response effect on the delayed CERAD-WL delayed-recall
test, with the weakest performance among patients within the
homozygote e4 group. In diagnosis-specific analyses, however,
this dose response did not reach statistical significance, likely due
to low statistical power. Memory decline is also seen in healthy
e4 carriers compared to non-carriers (Caselli et al., 2009). In
children it is reported that e4 carriers have smaller entorhinal
cortexes compared to non-carriers, which could possibly be
interpreted as a developmental effect (Shaw et al., 2007). One
will rarely see this effect on cognition in children, and it has
been suggested that memory impairment becomes manifest after
age 64 (Rawle et al., 2018). Homozygote carriers will present
with most memory impairment (Rawle et al., 2018). Thus, it is
possible that the observed reduction of episodic memory among
e4 carriers is due not only to AD in a preclinical (MCI) or
dementia stage but could just as well be a genetic cause of reduced
development of the hippocampal area and thus be related to
reduced memory performance that will occur in late life. Our
findings could be interpreted in line with such an assumption
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FIGURE 1 | Mean cognitive scores on four cognitive tests (A–D) (with 95% CI bands) by e4 status and diagnosis (left panel), and predicted difference in cognitive
scores for those without the e4 allele or homozygote e4 compared to those with monozygotic e4 (right panel).
or theory. Further findings could support our assumption/theory:
Only scores on the CERAD-WL (especially delayed recall) were
associated with the APO E e4 status across diagnoses. We saw no
associations between e4 genotype and processing speed, scores on
the MMSE, or TMTA. Therefore, the other cognitive deficits may
not be related to the e4 allele, or they may be secondary to poor
episodic memory.
Comparing the dementia groups, no differences were found
among the AD and AD/VaD groups on the MMSE. On the
TMTA, the AD group performed better than the AD/VaD
group. Thus, the memory effect of the e4 allele does not
seem to be specific to AD, because the same effect is seen
in the diagnostic groups of SCD and MCI. There is a higher
prevalence of the APOE-e4 allele is the AD group, however,
and performance impairment on the CERAD-WL is larger in
the AD than in any of the other diagnostic groups, especially
for delayed recall. The large cognitive deficits on the delayed
word list recall in AD may therefore be attributed to factors
other than the APOE e4 allele. Nevertheless, the allele seems
to be at least partly responsible for the memory problems
related to word list recall. Looking at our data, and in line
with Caselli et al. (2009) and Rawle et al. (2018) we suggest
that the e4 allele probably influence the aging process of the
brain. Those with the e4 allele as a group may have fewer
brain reserves as part of the aging process. Not everyone
with e4 allele will develop dementia, however, which probably
indicates great variation. To have the e4 allele is probably
neither sufficient nor necessary for developing dementia—
neither AD nor VaD, even though it is a strong risk factor.
The gene may contribute to the memory difficulties, however,
especially delayed recall.
Limitations
This study has some limitations. First, its cross-sectional design
makes it impossible to observe who will develop dementia
belonging to the SCD and MCI diagnostic groups. Some of these
patients may have AD in an early, preclinical stage. Second,
we have not included neuropsychological tests that cover most
cognitive domains, and thus cannot be sure that APOE genotype
may be associated with other cognitive domains in addition to
memory. A strength of the study is the large sample with patients
who have been examined comprehensively and diagnosed with
standardized criteria.
Conclusion
Our interpretation of the data is that the APOE e4 allele may
contribute to the development of dementia, but the association
between the e4 allele and the delayed recall test is also seen in
the SCD and MCI groups. However, this is a cross-sectional
study and the data needs to be confirmed in other kinds of
studies. We, nevertheless, suggest that the effects of e4 allele
can make the brain more vulnerable to dysfunction, which,
in turn, could reduce brain reserves and contribute to the
development of dementia.
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